News

Hepcludex (bulevirtide) is the first medication for the treatment of hepatitis D, a virus blocker whose development had been masterminded by DZIF Professor Dr Stephan Urban of Heidelberg University

Professor Rolf Müller, Managing Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has been awarded the Gottfried Wilhelm Leibniz Prize by the German Research Foundation

Scientists at the Research Center Borstel and the German Center for Infection Research (DZIF) identified a multidrug resistant Tuberculosis-strain in Southern Africa, that is not detected by modern

This year, the German Center for Infection Research (DZIF) is honouring two researchers who have been engaged in virus research for many years and are currently actively working on a vaccine against

As part of the research activities within the German Center for Infection Research (DZIF), scientists of the Paul-Ehrlich-Institut studied specific vaccine candidates against COVID-19. They are based

The organization CARB-X globally supports projects, which develop new drugs against antibiotic-resistant pathogens. Since the beginning of 2019 the DZIF is one of seven members in the CARB-X

Willingness to volunteer for COVID-19 vaccine trials is high. But what trials are underway and who can be contacted for further information? To answer these questions and to match interested

For the first time, Seoul virus could be identified as the cause of hantavirus disease in a German patient. Scientists from the Friedrich-Loeffler-Institut (FLI), the National Consiliary Laboratory

Joint press release of the DZIF and the Heidelberg University Hospital

Malaria parasites of the species Plasmodium need the Anopheles mosquito to enter the human body. In turn, mosquito larvae need

Based on data involving more than 80,000 patients, an international research group has developed a programme that can predict the individual risk of tuberculosis. The results of this work were